Trending...
- Independent Global Film Movement Tackles Diversity Issues At The 75th Festival De Cannes
- eBookFairs.com Acquires Pen It! Publications, LLC
- Jessica Ross Graces the Cover of Center Stage Magazine
What I Wish I Knew a Year Ago About the Aesthetic Market and Where I'm Investing Now
VANCOUVER, British Columbia - Californer -- In 1978, scientists isolated human insulin produced by genetically modified E. coli, marking the first biopharmaceutical derived from recombinant DNA technology. This radically new methodology for isolating enzymes and active ingredients shook biotechnology to the core, triggering a tsunami of discoveries. Since then, more than 250 therapeutic proteins and monoclonal antibodies have stolen the stage as standard of care.
In the last several years, this momentum carried over to cosmetics, as biotechnology and aesthetic medicines joined forces to isolate anti-aging skin products such as hyaluronic acid, kojic acid, and resveratrol, to name a few. But what new developments stand on the horizon? And to which direction should investors hone their gaze? Two emerging therapies, stem cell exosomes and gene therapy, scintillate brightly on the financial horizon as golden investment opportunities.
The global biotech aesthetic market size valued at USD 63.5 billion in 2021, with the compound annual growth rate (CAGR) projected to increase by 9.6% from 2022 to 2023, according to the aesthetic medicine market size report. Social distancing, sudden cuts in consumers' income levels, and temporary closures of beauty centers balanced the inevitable bottleneck in manufacturing and supply chains. The pandemic, however, saw the workforce shift to remote Zoom calls, forcing many to pay close attention to facial appearance. The market consequently saw a spike in non-invasive aesthetic treatments, with this segment dominating the market in 2021 with shares over 50%. The non-invasive aesthetic treatment market size was valued at USD 52 billion last year with a CAGR of 12.4%.
More on The Californer
Currently, 45 market competitors compose the exosome industry, with 19 of them being established companies that have recently joined the race to develop aging-defying exosome technology. Some of these companies include: Galderma S.A., Johnson & Johnson, Allergen, El. En. SpA, Alma Lasers, Cynosure, Lumenis, Solta Medical, Syneron Candela, and Merz Pharma.
Up and coming regenerative biotech company Elevai shows award winning promise with stem cell exosome topical applications as the next generation of targeted anti-aging skin care. Elevai recently won the LaunchPad SBDC People's Choice Award at the 2022 Octane Aesthetics Tech Summit ("ATS") held in Newport Beach, California, for their proprietary stem cell exosome technology and products. The Elevai platform technology illuminates potential applications in regenerative medicine and in office medical skincare treatments.
Another company worth mentioning includes Jeune, a gene-based aesthetic subsidiary of Krystal biotech, that is currently operating the first-in-human Phase 1 clinical trial of an injectable gene therapy to stimulate production of collagen type III and reduce wrinkles. The injections were well tolerated and biopsies at the injection sites showed new collagen generation, an excellent first step to directly address biological changes in the skin associated with intrinsic and extrinsic aging.
More on The Californer
Stem cell exosomes and gene therapy technologies will no doubt become the in office standard of care for regenerative and anti-aging technology, stealing the stage much in the same way that insulin radically changed diabetic care.
In the last several years, this momentum carried over to cosmetics, as biotechnology and aesthetic medicines joined forces to isolate anti-aging skin products such as hyaluronic acid, kojic acid, and resveratrol, to name a few. But what new developments stand on the horizon? And to which direction should investors hone their gaze? Two emerging therapies, stem cell exosomes and gene therapy, scintillate brightly on the financial horizon as golden investment opportunities.
The global biotech aesthetic market size valued at USD 63.5 billion in 2021, with the compound annual growth rate (CAGR) projected to increase by 9.6% from 2022 to 2023, according to the aesthetic medicine market size report. Social distancing, sudden cuts in consumers' income levels, and temporary closures of beauty centers balanced the inevitable bottleneck in manufacturing and supply chains. The pandemic, however, saw the workforce shift to remote Zoom calls, forcing many to pay close attention to facial appearance. The market consequently saw a spike in non-invasive aesthetic treatments, with this segment dominating the market in 2021 with shares over 50%. The non-invasive aesthetic treatment market size was valued at USD 52 billion last year with a CAGR of 12.4%.
More on The Californer
- EmpireXclusive Has a Big Weekend Ahead with ABIS Awards Gala and B.Simone Beauty Pop Up
- CORRECTING and REPLACING Innovaccer Unveils ACO REACH Accelerator Toolkit
- InventHelp Presents Durable Cane Tip (RSM-108)
- San Jose: Public Draft Review MND: 1975 Cambrianna Drive Residential Project
- Housing Market Slowing by Design, According to First American Real House Price Index
Currently, 45 market competitors compose the exosome industry, with 19 of them being established companies that have recently joined the race to develop aging-defying exosome technology. Some of these companies include: Galderma S.A., Johnson & Johnson, Allergen, El. En. SpA, Alma Lasers, Cynosure, Lumenis, Solta Medical, Syneron Candela, and Merz Pharma.
Up and coming regenerative biotech company Elevai shows award winning promise with stem cell exosome topical applications as the next generation of targeted anti-aging skin care. Elevai recently won the LaunchPad SBDC People's Choice Award at the 2022 Octane Aesthetics Tech Summit ("ATS") held in Newport Beach, California, for their proprietary stem cell exosome technology and products. The Elevai platform technology illuminates potential applications in regenerative medicine and in office medical skincare treatments.
Another company worth mentioning includes Jeune, a gene-based aesthetic subsidiary of Krystal biotech, that is currently operating the first-in-human Phase 1 clinical trial of an injectable gene therapy to stimulate production of collagen type III and reduce wrinkles. The injections were well tolerated and biopsies at the injection sites showed new collagen generation, an excellent first step to directly address biological changes in the skin associated with intrinsic and extrinsic aging.
More on The Californer
- NAAB Radio Now Streaming on iHeartRadio & BET Awards Weekend Events
- What is the process to change flights on JetBlue?
- MG Properties Acquires Verona Apartments in Henderson, NV
- How do I change or reset my password on Facebook
- Hiscox Harnesses CoreLogic Geocoding Technology to Assess Insurance Risks
Stem cell exosomes and gene therapy technologies will no doubt become the in office standard of care for regenerative and anti-aging technology, stealing the stage much in the same way that insulin radically changed diabetic care.
Source: Braeden William Lichti
0 Comments
Latest on The Californer
- San Francisco: Mayor London Breed and Supervisors Matt Dorsey and Rafael Mandelman Announce Budget Investment to Reduce HIV Infections
- San Jose: San José Mayor Marks One Year Since VTA Rail Yard Tragedy
- Unrooted Celebrates July 4th with a "Made In Amerikuhh" Wine Club
- Instacart Announces New Shoppable Video and Display Advertising Products, Driving Inspiration, Discovery and Purchase
- Namify gives restaurateurs a chance at effective branding with its Restaurant Name Generator
- eBookFairs.com Acquires Pen It! Publications, LLC
- Gigamon Releases "2022 TLS Trends Research" Based on 1.3 Trillion Network Flows
- Bratz® Makes History with Groundbreaking Pride Collector Dolls in Collaboration with Celebrity Designer Jimmy Paul and Licensed Lifestyle Manufacturer Difuzed
- Joby Receives Part 135 Certification from the FAA
- Picrorrhiza (KATUKI) an Excellent Liver Tonic Ayurvedic Herb, By Dr. Abhay Kumar Pati, DSc
- How do I become an American Airlines Travel Agent
- Winner: "America's #1 Distraction 2022" Chef PlayMeiT for ABHR Memorial Day Edition
- Armorblox Email Security Threat Report Reveals Huge Uptick in Language-Based Business Email Compromise Attacks
- GoodLoan.io provides update on current mortgage interest rates
- California Senate Votes to Support CARE Court, as Leading State Business Organizations Join Expanding Coalition
- CORRECTING and REPLACING CAPTION BSI Wins Best Biotech Startup Business of the Year 2022 Award
- Wigs to Create the Perfect Hairstyle for Graduation Season Are Coming
- Jessica Ross Graces the Cover of Center Stage Magazine
- PEGA Investor Alert: Robbins LLP Remind Shareholders of Class Action Against Pegasystems Inc. (PEGA)
- All-optical computation of a group of transformations using polarization-encoded diffractive network